Review of the COMMANDS Trial

Author(s):

Guillermo Garcia-Manero, MDRami Komrokji, MD

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

Now Viewing

EP: 4.Review of the COMMANDS Trial

EP: 5.Practing Changing? Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice

Dr Garcia-Manero: Briefly summarize the COMMANDS trial, evaluating luspatercept in patients with lower-risk MDS (Platzbecker U et al. Lancet Onco 2023).
1. Briefly comment on the study design, patient population, and primary/secondary endpoints.